Ceritinib Beim ROS1-positiven NSCLC

Im Focus Onkologie
doi 10.1007/s15015-017-3549-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Überlebensvorhersage Beim NSCLC

Im Focus Onkologie
2016English

P1.09-09 Evaluation of a Novel ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in NSCLC Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

CD99 — Neuer Stroma-Marker Mit Prognostischem Wert Beim NSCLC

Im Focus Onkologie
2013English

Partial Response to Ceritinib in a Patient With Abdominal Inflammatory Myofibroblastic Tumor Carrying a TFG-ROS1 Fusion

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2019English

OA02.02 Safety and Preliminary Clinical Activity of Ropotrectinib (TPX-0005), a ROS1/TRK/ALK Inhibitor, in Advanced ROS1 Fusion-Positive NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.09-12 Simultaneous Platform of Genotyping EGFR, ALK, and ROS1 in Patients With NSCLC Highlights Correlation of ROS1 and PD-L1 Expression

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Eine Studie Mit Positiven Nebenwirkungen

PrimaryCare
2015English

Die Positiven Nebenwirkungen Des Coronavirus

Schweizerische Ärztezeitung
2020English

Die Positiven Nebenwirkungen Des Coronavirus

Bulletin des Médecins Suisses
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy